# Octapharma clinical trials: 71 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 71 trials with Octapharma as lead sponsor, 8 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Octapharma: 71 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/octapharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 71
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 25 newest of 71, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 24, 2025 | NCT07220915 | Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Octapharma | Phase 3 | Recruiting | Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220915) |
| May 28, 2024 | NCT06429787 | Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults... | Octapharma | Observational | Active not recruiting | Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk | 3,574 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06429787) |
| April 12, 2024 | NCT06361537 | Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and... | Octapharma | Phase 3 | Recruiting | Acute Hereditary Angio Edema | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06361537) |
| October 23, 2023 | NCT06096116 | Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo... | Octapharma | Phase 3 | Recruiting | Acquired Antithrombin Deficiency | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06096116) |
| July 10, 2023 | NCT05936580 | Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery | Octapharma | Phase 4 | Recruiting | Hemophilia A | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05936580) |
| July 7, 2023 | NCT05935358 | Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | Octapharma | Phase 4 | Recruiting | Severe Hemophilia A | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05935358) |
| August 31, 2022 | NCT05523297 | Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery | Octapharma | Phase 3 | Completed | Bleeding Cardiac Surgery Patients | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05523297) |
| July 8, 2021 | NCT04953884 | Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients \<6 Years of Age | Octapharma | Phase 3 | Completed | Von Willebrand Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04953884) |
| June 18, 2021 | NCT04929236 | Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating... | Octapharma | Phase 3 | Recruiting | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04929236) |
| June 8, 2021 | NCT04918173 | Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery | Octapharma | Phase 3 | Recruiting | Congenital Antithrombin Deficiency | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04918173) |
| April 30, 2021 | NCT04867837 | Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor | Octapharma | Phase 3 | Terminated | Acute Major Bleeding | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867837) |
| December 3, 2020 | NCT04651400 | Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe... | Octapharma | Observational | Completed | Covid19 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04651400) |
| November 23, 2020 | NCT04640142 | Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With... | Octapharma | Phase 3 | Active not recruiting | Primary Immune Deficiency | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04640142) |
| August 11, 2020 | NCT04508530 | Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome... | Octapharma | Phase 3 | Completed | Pediatric Acute-Onset Neuropsychiatric Syndrome | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04508530) |
| August 6, 2020 | NCT04502030 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection... | Octapharma | Phase 3 | Completed | Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04502030) |
| May 22, 2020 | NCT04400058 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | Octapharma | Phase 3 | Completed | Covid-19 | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04400058) |
| September 27, 2019 | NCT04106908 | Effectiveness and Tolerability of Eqwilate in Real-life Conditions | Octapharma | Observational | Active not recruiting | VWD - Von Willebrand's Disease | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04106908) |
| September 27, 2019 | NCT04106895 | Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data | Octapharma | Observational | Completed | Bleeding | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04106895) |
| August 12, 2019 | NCT04053699 | Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment | Octapharma | Observational | Completed | Von Willebrand Diseases | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04053699) |
| August 12, 2019 | NCT04052698 | Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD | Octapharma | Phase 3 | Completed | Von Willebrand Diseases | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04052698) |
| August 6, 2019 | NCT04046848 | Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A | Octapharma | Phase 1/2 | Terminated | Severe Hemophilia A | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04046848) |
| June 17, 2019 | NCT03988426 | Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases | Octapharma | Phase 3 | Completed | Primary Immune Deficiency Disorder | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03988426) |
| May 6, 2019 | NCT03939533 | Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency... | Octapharma | Phase 3 | Completed | Primary Immune Deficiency Disorder | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03939533) |
| April 8, 2019 | NCT03907241 | CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH... | Octapharma | Phase 3 | Completed | Primary Immunodeficiency | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03907241) |
| March 7, 2019 | NCT03866798 | Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) | Octapharma | Phase 4 | Terminated | Chronic Immune Thrombocytopenia | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03866798) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 39 |
| Phase 4 | 7 |
| Not applicable | 1 |
| Observational | 17 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 47 |
| Terminated | 12 |
| Recruiting | 8 |
| Active not recruiting | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemophilia A | 15 |
| Primary Immunodeficiency Diseases | 10 |
| von Willebrand Diseases | 5 |
| Hemostatic Disorders | 3 |
| Purpura, Thrombotic Thrombocytopenic | 3 |
| Hemophilia B | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| COVID-19 | 2 |
| Dermatomyositis | 2 |
| Agammaglobulinemia | 2 |
| Vitamin K-Dependent Clotting Factors, Combined Deficiency Of, 1 | 1 |
| Afibrinogenemia | 1 |
| Antithrombin III Deficiency | 1 |
| Liver Diseases | 1 |
| Blood Coagulation Disorders, Inherited | 1 |
| Blood Coagulation Disorders | 1 |
| Hematologic Diseases | 1 |
| Coagulation Protein Disorders | 1 |
| Hemorrhagic Disorders | 1 |
| Genetic Diseases, Inborn | 1 |
| alpha 1-Antitrypsin Deficiency | 1 |
| Immunologic Deficiency Syndromes | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Hemorrhage | 1 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
- [Honduran restaurants in the United States](https://specstream.ai/data/businesses/honduran-restaurants/united-states)
- [Plasterers in the United States](https://specstream.ai/data/businesses/plasterers/united-states)
- [Waste collection companies in the United States](https://specstream.ai/data/businesses/waste-collection-companies/united-states)
- [Cleaning companies in the United States](https://specstream.ai/data/businesses/cleaning-companies/united-states)
